Literature DB >> 6293835

Distribution of oral ketoconazole to vaginal tissue.

J J Heykants, R J Woestenborghs, M P Bisschop, J M Merkus.   

Abstract

Plasma samples and biopsies of vaginal tissue were obtained from 23 healthy women undergoing operative sterilization, 1 to 6 h after a single oral dose of ketoconazole 200 mg. Drug concentrations in plasma and tissue, were measured by a specific gas chromatographic method. The vaginal tissue concentration averaged 2.4 times less than the corresponding plasma levels. Equilibrium between tissue, and plasma was established within 1 h after dosing, when vaginal tissue levels exceeded 1 microgram/g. Ketoconazole concentrations decayed monoexponentially over the time interval studied (1-6h), with the similar half-lives of 1.2 and 1.4 H in plasma and tissue, respectively. Following an oral 200 mg dose, a tissue concentration not less than 0.01 microgram/ml was maintained over a 12 h period. This concentration has been shown to prevent outgrowth of the invasive (pseudo) mycelial form of Candida albicans. Hence, a b.i.d. or t.i.d. dosage schedule of ketoconazole in vaginal candidosis would give continuously effective levels at the site of infection. Ketoconazole concentrations in vaginal fluid are thought to be much higher than in the tissue because of ion-trapping. The present data may explain the efficacy of oral ketoconazole in the treatment of vaginal candidosis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6293835     DOI: 10.1007/bf00613615

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Passage of drugs across body membranes.

Authors:  L S SCHANKER
Journal:  Pharmacol Rev       Date:  1962-12       Impact factor: 25.468

2.  Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic.

Authors:  M P Bisschop; J M Merkus; H Scheygrond; J Van Cutsem; A van de Kuy
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1979-08       Impact factor: 2.435

3.  An evaluation of two years of clinical experience with ketoconazole.

Authors:  J Symoens; M Moens; J Dom; H Scheijgrond; J Dony; V Schuermans; R Legendre; N Finestine
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

Review 4.  Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives.

Authors:  M Borgers
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

5.  Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent.

Authors:  J Heeres; L J Backx; J H Mostmans; J Van Cutsem
Journal:  J Med Chem       Date:  1979-08       Impact factor: 7.446

6.  Ketoconazole in experimental candidosis.

Authors:  D Thienpont; J Van Cutsem; M Borgers
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug
  6 in total
  2 in total

Review 1.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

Review 2.  Antiretroviral pharmacology in mucosal tissues.

Authors:  Corbin G Thompson; Myron S Cohen; Angela D M Kashuba
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.